Asia Pacific Clinical Trials Market Forecast to 2028 – Regional Analysis – by Study Design (Interventional, Observational, and Expanded Access), Phase (Phase I, Phase II, Phase III, and Phase IV), and Indication (Autoimmune/Inflammation, Pain Management, Oncology, CNS Condition, Diabetes, Obesity, Cardiovascular, and Others)
The Asia Pacific clinical trials market is expected to grow from US$ 8,670.68 million in 2022 to US$ 13,114.04 million by 2028. It is estimated to grow at a CAGR of 7.1% from 2022 to 2028.
AI-Driven Clinical Trials Fuels Asia Pacific Clinical Trials Market
Adoption of Artificial Intelligence (AI) offers innovative ways to collect and manage clinical trial data and reduces dependency on manual operations. Thus, AI acts as a game changer for life science companies involved in the drug development process.
The Oncology Data Science team at AstraZeneca feeds these data into a system that utilizes AI and other statistical tools to generate novel hypotheses for oncology drug development. To transform the process of oncology data feed, the team is adopting complex datasets for accessibility, interoperability, and reusability of data as per 'GOFAIR (Findability, Accessibility, Interoperability, and Reuse of digital assets)'—the set of principles. Such integration empowers data collection from specific clinical trials and projects to be accessible across the company's drug development teams in compliance with data protection laws.
AstraZeneca is collaborated with companies such as Tempus to leverage real-world data and represent patients globally. Such strategic partnerships are anticipated to offer crucial evidence about patient outcomes without revealing the identification of the clinical trial participants in the datasets.
Asia Pacific Clinical Trials Market Overview
Asia Pacific (APAC) is the fastest-growing regional market for global clinical trials and is segmented into China, Japan, India, South Korea, Australia, Indonesia, Thailand, Vietnam, and the Rest of Asia Pacific. Countries such as Australia, India, and South Korea are estimated to witness various growth opportunities due to the rising development in the healthcare sector. In addition, governments of these countries are increasing their efforts to provide clinical trials. Also, rise in the incidence of chronic diseases and growing awareness regarding clinical trials are likely to offer greater growth opportunities to the market players in the coming years.
Asia Pacific clinical trials market Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Clinical Trials Market Segmentation
The Asia Pacific clinical trials market is segmented into phase, study design, indication, and country.
Based on phase, the Asia Pacific clinical trials market is segmented into phase I, phase II, phase III, and phase IV. The phase III segment registered the largest Asia Pacific clinical trials market share in 2022.
Based on study design, the Asia Pacific clinical trials market is segmented into interventional, observational, and expanded access. The interventional segment held the largest Asia Pacific clinical trials market share in 2022.
Based on indication, the Asia Pacific clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, CNS condition, diabetes, obesity, cardiovascular, and others. The oncology segment held the largest Asia Pacific clinical trials market share in 2022.
Based on country, the Asia Pacific clinical trials market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific clinical trials market in 2022.
Charles River Laboratories International Inc, ICON Plc, IQVIA Holdings Inc, Laboratory Corp of America Holdings, Parexel International Corp, SGS SA, SIRO Clinpharm Pvt Ltd, Syneos Health Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd. are some of the leading companies operating in the Asia Pacific clinical trials market.
AI-Driven Clinical Trials Fuels Asia Pacific Clinical Trials Market
Adoption of Artificial Intelligence (AI) offers innovative ways to collect and manage clinical trial data and reduces dependency on manual operations. Thus, AI acts as a game changer for life science companies involved in the drug development process.
The Oncology Data Science team at AstraZeneca feeds these data into a system that utilizes AI and other statistical tools to generate novel hypotheses for oncology drug development. To transform the process of oncology data feed, the team is adopting complex datasets for accessibility, interoperability, and reusability of data as per 'GOFAIR (Findability, Accessibility, Interoperability, and Reuse of digital assets)'—the set of principles. Such integration empowers data collection from specific clinical trials and projects to be accessible across the company's drug development teams in compliance with data protection laws.
AstraZeneca is collaborated with companies such as Tempus to leverage real-world data and represent patients globally. Such strategic partnerships are anticipated to offer crucial evidence about patient outcomes without revealing the identification of the clinical trial participants in the datasets.
Asia Pacific Clinical Trials Market Overview
Asia Pacific (APAC) is the fastest-growing regional market for global clinical trials and is segmented into China, Japan, India, South Korea, Australia, Indonesia, Thailand, Vietnam, and the Rest of Asia Pacific. Countries such as Australia, India, and South Korea are estimated to witness various growth opportunities due to the rising development in the healthcare sector. In addition, governments of these countries are increasing their efforts to provide clinical trials. Also, rise in the incidence of chronic diseases and growing awareness regarding clinical trials are likely to offer greater growth opportunities to the market players in the coming years.
Asia Pacific clinical trials market Revenue and Forecast to 2028 (US$ Million)
Asia Pacific Clinical Trials Market Segmentation
The Asia Pacific clinical trials market is segmented into phase, study design, indication, and country.
Based on phase, the Asia Pacific clinical trials market is segmented into phase I, phase II, phase III, and phase IV. The phase III segment registered the largest Asia Pacific clinical trials market share in 2022.
Based on study design, the Asia Pacific clinical trials market is segmented into interventional, observational, and expanded access. The interventional segment held the largest Asia Pacific clinical trials market share in 2022.
Based on indication, the Asia Pacific clinical trials market is segmented into autoimmune/inflammation, pain management, oncology, CNS condition, diabetes, obesity, cardiovascular, and others. The oncology segment held the largest Asia Pacific clinical trials market share in 2022.
Based on country, the Asia Pacific clinical trials market has been categorized into China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific clinical trials market in 2022.
Charles River Laboratories International Inc, ICON Plc, IQVIA Holdings Inc, Laboratory Corp of America Holdings, Parexel International Corp, SGS SA, SIRO Clinpharm Pvt Ltd, Syneos Health Inc, Thermo Fisher Scientific Inc, and WuXi AppTec Co Ltd. are some of the leading companies operating in the Asia Pacific clinical trials market.
1. INTRODUCTION
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Clinical Trials Market – By Phase
1.3.2 Asia Pacific Clinical Trials Market – By Study Design
1.3.3 Asia Pacific Clinical Trials Market – By Indication
1.3.4 Asia Pacific Clinical Trials Market – By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. ASIA PACIFIC CLINICAL TRIALS MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific PEST Analysis
4.3 Experts Opinion
5. ASIA PACIFIC CLINICAL TRIALS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Adoption and Outsourcing of Clinical Trials
5.1.2 Flourishing Pharmaceutical Industry and Increasing R&D Activities in Pharmaceutical Industry
5.2 Market Restraints
5.2.1 Expensive and Time-Consuming Process
5.3 Market Opportunities
5.3.1 Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials
5.4 Future Trends
5.4.1 AI-Driven Clinical Trials
5.5 Impact Analysis
6. CLINICAL TRIALS MARKET – ASIA PACIFIC ANALYSIS
6.1 Asia Pacific Clinical Trials Market Revenue Forecast and Analysis
7. ASIA PACIFIC CLINICAL TRIALS MARKET REVENUE AND FORECAST TO 2028 – BY STUDY DESIGN
7.1 Overview
7.2 Asia Pacific Clinical Trials Market Revenue Share, by Study Design (2022 and 2028)
7.3 Interventional
7.3.1 Overview
7.3.2 Interventional: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Observational
7.4.1 Overview
7.4.2 Observational: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Expanded Access
7.5.1 Overview
7.5.2 Expanded Access: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8. ASIA PACIFIC CLINICAL TRIALS MARKET – BY PHASE
8.1 Overview
8.2 Asia Pacific Clinical Trials Market, by Phase, 2022 and 2028 (%)
8.3 Phase III
8.3.1 Overview
8.3.2 Phase III: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Phase II
8.4.1 Overview
8.4.2 Phase II: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Phase IV
8.5.1 Overview
8.5.2 Phase IV: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Phase I
8.6.1 Overview
8.6.2 Phase I: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9. ASIA PACIFIC CLINICAL TRIALS MARKET REVENUE AND FORECAST TO 2028 – INDICATION
9.1 Overview
9.2 Asia Pacific Clinical Trials Market Revenue Share, by Indication (2022 and 2028)
9.3 Autoimmune/Inflammation
9.3.1 Overview
9.3.2 Autoimmune/Inflammation: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Pain Management
9.4.1 Overview
9.4.2 Pain Management: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Oncology
9.5.1 Overview
9.5.2 Oncology: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.6 CNS Condition
9.6.1 Overview
9.6.2 CNS Condition: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.7 Diabetes
9.7.1 Overview
9.7.2 Diabetes: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.8 Obesity
9.8.1 Overview
9.8.2 Obesity: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.9 Cardiovascular
9.9.1 Overview
9.9.2 Cardiovascular: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.10 Other
9.10.1 Overview
9.10.2 Other: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10. ASIA PACIFIC CLINICAL TRIALS MARKET – REVENUE AND FORECAST TO 2028 – COUNTRY ANALYSIS
10.1.1 Asia Pacific: Clinical Trials Market
10.1.1 Overview
10.1.1.1 China: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 China: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.3 China: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.1.1.4 China: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.1.1.5 China: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
10.1.1.2 Japan: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Japan: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.3 Japan: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.1.2.4 Japan: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.1.2.5 Japan: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
10.1.1.3 India: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 India: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.3 India: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.1.3.4 India: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.1.3.5 India: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
10.1.1.4 Australia: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Australia: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.3 Australia: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.1.4.4 Australia: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.1.4.5 Australia: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
10.1.1.5 South Korea: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 South Korea: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.3 South Korea: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.1.5.4 South Korea: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.1.5.5 South Korea: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
10.1.1.6 Rest of Asia Pacific: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Asia Pacific: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.3 Rest of Asia Pacific: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.1.6.4 Rest of Asia Pacific: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.1.6.5 Rest of Asia Pacific: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
11. INDUSTRY LANDSCAPE
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. COMPANY PROFILES
12.1 IQVIA Holdings Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Parexel International Corp
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Charles River Laboratories International Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 ICON Plc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 WuXi AppTec Co Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 SGS SA
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Syneos Health Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 SIRO Clinpharm Pvt Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Thermo Fisher Scientific Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Laboratory Corp of America Holdings
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. APPENDIX
13.1 About The Insight Partners
13.2 Glossary of Terms
1.1 Scope of the Study
1.2 The Insight Partners Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Clinical Trials Market – By Phase
1.3.2 Asia Pacific Clinical Trials Market – By Study Design
1.3.3 Asia Pacific Clinical Trials Market – By Indication
1.3.4 Asia Pacific Clinical Trials Market – By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. ASIA PACIFIC CLINICAL TRIALS MARKET – MARKET LANDSCAPE
4.1 Overview
4.2 PEST Analysis
4.2.1 Asia Pacific PEST Analysis
4.3 Experts Opinion
5. ASIA PACIFIC CLINICAL TRIALS MARKET – KEY MARKET DYNAMICS
5.1 Market Drivers
5.1.1 Increasing Adoption and Outsourcing of Clinical Trials
5.1.2 Flourishing Pharmaceutical Industry and Increasing R&D Activities in Pharmaceutical Industry
5.2 Market Restraints
5.2.1 Expensive and Time-Consuming Process
5.3 Market Opportunities
5.3.1 Adoption of Decentralized Clinical Trials and Hybrid Clinical Trials
5.4 Future Trends
5.4.1 AI-Driven Clinical Trials
5.5 Impact Analysis
6. CLINICAL TRIALS MARKET – ASIA PACIFIC ANALYSIS
6.1 Asia Pacific Clinical Trials Market Revenue Forecast and Analysis
7. ASIA PACIFIC CLINICAL TRIALS MARKET REVENUE AND FORECAST TO 2028 – BY STUDY DESIGN
7.1 Overview
7.2 Asia Pacific Clinical Trials Market Revenue Share, by Study Design (2022 and 2028)
7.3 Interventional
7.3.1 Overview
7.3.2 Interventional: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
7.4 Observational
7.4.1 Overview
7.4.2 Observational: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
7.5 Expanded Access
7.5.1 Overview
7.5.2 Expanded Access: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8. ASIA PACIFIC CLINICAL TRIALS MARKET – BY PHASE
8.1 Overview
8.2 Asia Pacific Clinical Trials Market, by Phase, 2022 and 2028 (%)
8.3 Phase III
8.3.1 Overview
8.3.2 Phase III: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8.4 Phase II
8.4.1 Overview
8.4.2 Phase II: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8.5 Phase IV
8.5.1 Overview
8.5.2 Phase IV: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
8.6 Phase I
8.6.1 Overview
8.6.2 Phase I: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9. ASIA PACIFIC CLINICAL TRIALS MARKET REVENUE AND FORECAST TO 2028 – INDICATION
9.1 Overview
9.2 Asia Pacific Clinical Trials Market Revenue Share, by Indication (2022 and 2028)
9.3 Autoimmune/Inflammation
9.3.1 Overview
9.3.2 Autoimmune/Inflammation: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.4 Pain Management
9.4.1 Overview
9.4.2 Pain Management: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.5 Oncology
9.5.1 Overview
9.5.2 Oncology: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.6 CNS Condition
9.6.1 Overview
9.6.2 CNS Condition: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.7 Diabetes
9.7.1 Overview
9.7.2 Diabetes: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.8 Obesity
9.8.1 Overview
9.8.2 Obesity: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.9 Cardiovascular
9.9.1 Overview
9.9.2 Cardiovascular: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
9.10 Other
9.10.1 Overview
9.10.2 Other: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10. ASIA PACIFIC CLINICAL TRIALS MARKET – REVENUE AND FORECAST TO 2028 – COUNTRY ANALYSIS
10.1.1 Asia Pacific: Clinical Trials Market
10.1.1 Overview
10.1.1.1 China: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.1 Overview
10.1.1.1.2 China: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.1.3 China: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.1.1.4 China: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.1.1.5 China: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
10.1.1.2 Japan: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.1 Overview
10.1.1.2.2 Japan: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.2.3 Japan: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.1.2.4 Japan: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.1.2.5 Japan: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
10.1.1.3 India: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.1 Overview
10.1.1.3.2 India: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.3.3 India: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.1.3.4 India: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.1.3.5 India: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
10.1.1.4 Australia: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.1 Overview
10.1.1.4.2 Australia: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.4.3 Australia: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.1.4.4 Australia: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.1.4.5 Australia: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
10.1.1.5 South Korea: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.1 Overview
10.1.1.5.2 South Korea: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.5.3 South Korea: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.1.5.4 South Korea: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.1.5.5 South Korea: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
10.1.1.6 Rest of Asia Pacific: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.1 Overview
10.1.1.6.2 Rest of Asia Pacific: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
10.1.1.6.3 Rest of Asia Pacific: Clinical Trials Market, by Phase, 2020–2028 (US$ Million)
10.1.1.6.4 Rest of Asia Pacific: Clinical Trials Market, by Study Design, 2020–2028 (US$ Million)
10.1.1.6.5 Rest of Asia Pacific: Clinical Trials Market, by Indication, 2020–2028 (US$ Million)
11. INDUSTRY LANDSCAPE
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. COMPANY PROFILES
12.1 IQVIA Holdings Inc
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Parexel International Corp
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Charles River Laboratories International Inc
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 ICON Plc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 WuXi AppTec Co Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 SGS SA
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Syneos Health Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 SIRO Clinpharm Pvt Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
12.9 Thermo Fisher Scientific Inc
12.9.1 Key Facts
12.9.2 Business Description
12.9.3 Products and Services
12.9.4 Financial Overview
12.9.5 SWOT Analysis
12.9.6 Key Developments
12.10 Laboratory Corp of America Holdings
12.10.1 Key Facts
12.10.2 Business Description
12.10.3 Products and Services
12.10.4 Financial Overview
12.10.5 SWOT Analysis
12.10.6 Key Developments
13. APPENDIX
13.1 About The Insight Partners
13.2 Glossary of Terms
LIST OF TABLES
Table 1. China Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 2. China Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 3. China Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 4. Japan Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 5. Japan Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 6. Japan Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 7. India Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 8. India Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 9. India Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 10. Australia Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 11. Australia Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 12. Australia Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 13. South Korea Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 14. South Korea Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 15. South Korea Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 16. Rest of Asia Pacific Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of Asia Pacific Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of Asia Pacific Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 19. Organic Developments Done by Companies
Table 20. Inorganic Developments Done by Companies
Table 21. Glossary of Terms
Table 1. China Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 2. China Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 3. China Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 4. Japan Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 5. Japan Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 6. Japan Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 7. India Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 8. India Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 9. India Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 10. Australia Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 11. Australia Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 12. Australia Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 13. South Korea Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 14. South Korea Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 15. South Korea Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 16. Rest of Asia Pacific Clinical Trials Market, by Phase – Revenue and Forecast to 2028 (US$ Million)
Table 17. Rest of Asia Pacific Clinical Trials Market, by Study Design – Revenue and Forecast to 2028 (US$ Million)
Table 18. Rest of Asia Pacific Clinical Trials Market, by Indication – Revenue and Forecast to 2028 (US$ Million)
Table 19. Organic Developments Done by Companies
Table 20. Inorganic Developments Done by Companies
Table 21. Glossary of Terms
LIST OF FIGURES
Figure 1. Asia Pacific Clinical Trials Market Segmentation
Figure 2. Asia Pacific Clinical Trials Market, By Region
Figure 3. Asia Pacific Clinical Trials Market Overview
Figure 4. Phase III Segment Held Largest Share of Phase Segment in Asia Pacific Clinical Trials Market
Figure 5. India is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Asia Pacific: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis
Figure 9. Asia Pacific Clinical Trials Market– Revenue Forecast and Analysis – 2020- 2028
Figure 10. Asia Pacific Clinical Trials Market Revenue Share, by Study Design (2022 and 2028)
Figure 11. Interventional: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Observational: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Expanded Access: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Asia Pacific Clinical Trials Market, by Phase 2022 and 2028 (%)
Figure 15. Phase III: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Phase II: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Phase IV: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Phase I: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Asia Pacific Clinical Trials Market Revenue Share, by Indication (2022 and 2028)
Figure 20. Autoimmune/Inflammation: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Pain Management: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Oncology: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. CNS Condition: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Diabetes: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Obesity: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Cardiovascular: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Other: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Asia Pacific: Clinical Trials Market, by Key Country – Revenue (2022) (US$ Million)
Figure 29. Asia Pacific: Clinical Trials Market, by Country, 2022 & 2028 (%)
Figure 30. China: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Japan: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. India: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Australia: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. South Korea: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Rest of Asia Pacific: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Growth Strategies Done by the Companies in the Market, (%)
Figure 1. Asia Pacific Clinical Trials Market Segmentation
Figure 2. Asia Pacific Clinical Trials Market, By Region
Figure 3. Asia Pacific Clinical Trials Market Overview
Figure 4. Phase III Segment Held Largest Share of Phase Segment in Asia Pacific Clinical Trials Market
Figure 5. India is Expected to Show Remarkable Growth During the Forecast Period
Figure 6. Asia Pacific: PEST Analysis
Figure 7. Experts Opinion
Figure 8. Impact Analysis
Figure 9. Asia Pacific Clinical Trials Market– Revenue Forecast and Analysis – 2020- 2028
Figure 10. Asia Pacific Clinical Trials Market Revenue Share, by Study Design (2022 and 2028)
Figure 11. Interventional: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 12. Observational: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 13. Expanded Access: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 14. Asia Pacific Clinical Trials Market, by Phase 2022 and 2028 (%)
Figure 15. Phase III: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 16. Phase II: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 17. Phase IV: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 18. Phase I: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 19. Asia Pacific Clinical Trials Market Revenue Share, by Indication (2022 and 2028)
Figure 20. Autoimmune/Inflammation: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 21. Pain Management: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 22. Oncology: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 23. CNS Condition: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 24. Diabetes: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 25. Obesity: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 26. Cardiovascular: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 27. Other: Asia Pacific Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 28. Asia Pacific: Clinical Trials Market, by Key Country – Revenue (2022) (US$ Million)
Figure 29. Asia Pacific: Clinical Trials Market, by Country, 2022 & 2028 (%)
Figure 30. China: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 31. Japan: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 32. India: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 33. Australia: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 34. South Korea: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 35. Rest of Asia Pacific: Clinical Trials Market – Revenue and Forecast to 2028 (US$ Million)
Figure 36. Growth Strategies Done by the Companies in the Market, (%)
